7 News & Press Releases found
NuMedii, Inc. News
-
NuMedii Announces Creation of World’s First Single-Cell Sequencing Atlas for Idiopathic Pulmonary Fibrosis by its Collaborators
SAN MATEO, Calif., July 9, 2020 /PRNewswire/ — NuMedii, Inc., a data-driven drug discovery company, today announced the availability of the world’s first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF) that was the ...
-
NuMedii Names Industry Veteran Heather Arnett, Ph.D. as Vice President of Research
SAN MATEO, Calif., November 1, 2018 – NuMedii, Inc., today announced the appointment of Heather Arnett, Ph.D., as Vice President, Research. Heather is leading research discovery and early development at NuMedii based on the company’s ...
-
NuMedii Announces Research Collaboration With Leading Academic Research Institution to Explore New Targets and Therapeutics for Pancreatitis
SAN MATEO, Calif., November 1, 2018 – NuMedii, Inc., today announced the formation of a research collaboration with Johns Hopkins School of Medicine with the goal of discovering new targets and therapeutic options for pancreatitis. The ...
-
NuMedii Announces Strategic Research Collaboration with Two Leading Academic Research Institutions Utilizing Single-Cell Sequencing to Identify Precision Therapeutics for IPF
SAN MATEO, Calif., July 10, 2018 – NuMedii, Inc., today announced the formation of a strategic research collaboration with Yale School of Medicine and Brigham and Women’s Hospital with the goal of utilizing single-cell sequencing to ...
-
NuMedii Advances IPF Personalized Medicine with New Advisory Board to Guide AI Approach
NuMedii is advancing the field of personalized medicine for idiopathic pulmonary fibrosis (IPF) by creating a new advisory board that includes some of the world’s leading specialists in interstitial lung disease to guide a new approach to ...
-
World’s Leading Lung Disease Experts Join NuMedii’s Idiopathic Pulmonary Fibrosis Advisory Board
MENLO PARK, Calif., January 8, 2018 – NuMedii, Inc. today announced the formation of an Idiopathic Pulmonary Fibrosis (IPF) Advisory Board consisting of the world’s leading experts in interstitial lung disease: Naftali Kaminski, MD; ...
-
NuMedii, Inc. Announces New Partnership To Discover and Advance New Treatments for Idiopathic Pulmonary Fibrosis
MENLO PARK, Calif., April 11, 2017 – NuMedii, Inc. today announced the formation of a strategic partnership with Three Lakes Partners, LLC, to discover and advance new treatments for idiopathic pulmonary fibrosis (IPF) based on ...